Prospective studies evaluating younger, fit patients eligible for IC compared to AZA-VEN
| Study . | Phase . | Type . | Therapy . | Key inclusion . | Key exclusion . |
|---|---|---|---|---|---|
| NCT04801797 | II | Randomized | • IC • AZA-VEN | • Age 18+ • ECOG ≤2 | • FLT3 • Age <60 with NPM1 mutated • Favorable risk |
| NCT03573024 | II | Single arm | • AZA-VEN | • Age 18-59 • ECOG ≤2 • Adverse risk | • Willing to receive IC |
| NCT05554393 (MyeloMATCH) | II | Randomized | • 7 + 3 • 7 + 3 + VEN • AZA-VEN | • Age 18-59 • ECOG 0-3 | • Favorable and adverse risk by ELN 2017 criteria • FLT3-ITD/TKD • Secondary or therapy-related AML |
| NCT05554406 (MyeloMATCH) | II | Randomized | • CPX-351 • 7 + 3 • AZA-VEN • 7 + 3+ VEN • CPX-351 + VEN | • Age 18-59 • ECOG 0-3 • Adverse risk per ELN 2017 criteria | • Favorable or intermediate risk • FLT3- ITD/TKD |
| Study . | Phase . | Type . | Therapy . | Key inclusion . | Key exclusion . |
|---|---|---|---|---|---|
| NCT04801797 | II | Randomized | • IC • AZA-VEN | • Age 18+ • ECOG ≤2 | • FLT3 • Age <60 with NPM1 mutated • Favorable risk |
| NCT03573024 | II | Single arm | • AZA-VEN | • Age 18-59 • ECOG ≤2 • Adverse risk | • Willing to receive IC |
| NCT05554393 (MyeloMATCH) | II | Randomized | • 7 + 3 • 7 + 3 + VEN • AZA-VEN | • Age 18-59 • ECOG 0-3 | • Favorable and adverse risk by ELN 2017 criteria • FLT3-ITD/TKD • Secondary or therapy-related AML |
| NCT05554406 (MyeloMATCH) | II | Randomized | • CPX-351 • 7 + 3 • AZA-VEN • 7 + 3+ VEN • CPX-351 + VEN | • Age 18-59 • ECOG 0-3 • Adverse risk per ELN 2017 criteria | • Favorable or intermediate risk • FLT3- ITD/TKD |